Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

ESC 2022 | Should We Follow-Up with Functional Testing in High-Risk Patients after CTA?

While the need for repeat cinecoronary angiography after transluminal coronary angioplasty (TCA) has decreased with the use of drug-eluting stents and improved medical treatment, patients still present ischemic recurrence or cardiovascular events at follow-up.

ESC 2022

Using a functional test at follow-up after TCA or myocardial revascularization (CMR) is a frequent practice in our context. This is why guidelines recommend (for Class IIb) a functional test in high-risk patients 6 months after TCA and 1 year after CRM. However, there is limited information from randomized studies for this recommendation.

The objective of this multicenter, randomized study was to determine the effect on clinical outcomes of a follow-up strategy that included routine functional testing in high-risk patients after TCA. 

The primary endpoint (PEP) was a composite of major cardiovascular events including all-cause death, acute myocardial infarction, or hospitalization for unstable angina at 2 years. The secondary endpoint (SEP) included the individual components of the PEP plus invasive coronary angiography and repeat revascularization.

The study randomized 1706 patients at several centers in South Korea to follow-up with functional testing at 1 year vs. conventional treatment alone. Mean patient age was 64 years old, and most patients were male. Regarding the complexity of the coronary lesions, 21% had left main coronary artery disease, 43% had coronary bifurcation disease, 69% had multivessel disease, 70% had diffuse disease, and 19% had acute coronary syndrome. The use of functional assessment by fractional flow reserve was 35% and the use of intravascular ultrasound was 74%.

Read also: ESC 2022 | INVICTUS and PRE18FFIR.

There was no difference in the PEP at 2 years (hazard ratio: 0.90; 95% confidence interval: 0.61-1.35; p = 0.62). Regarding the SEP, at 2 years, 12% of patients in the functional test group underwent cinecoronary angiography vs. 9% in the conventional treatment group. Furthermore, 8% of patients in the functional test group required repeat revascularization at follow-up compared with 5.8% in the other group.

Conclusion

In this study involving high-risk patients who underwent TCA, routine functional testing at follow-up compared with conventional treatment did not result in a lower risk of ischemic cardiovascular events or all-cause death at 2 years.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Routine Functional Testing or Standard Care in High-Risk Patients after PCI.

Reference: Duk‑Woo Park, M.D et al August 28, 2022, at NEJM. Presentado en ESC 2022.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...